Multiple Myeloma

A phase I study examines the use of LCAR-B38M, a CAR T-cell therapy directed against BCMA, in patients with relapsed/refractory multiple myeloma.

The study also looked at how lenalidomide maintenance further increases the rate of negative MRD results in multiple myeloma patients.

What's the most effective way to access frailty among multiple myeloma patients? Take our latest quiz to test your knowledge.

A new study shows benefits in curative treatment approaches to secondary cancers among patients with myeloma.

Undergoing bloodless autologous stem cell transplantation could be a viable option for some multiple myeloma patients according to a retrospective study.

Challenge yourself with our latest quiz covering management of AL amyloidosis in the treatment of patients with multiple myeloma.

Researchers examined adding daratumumab to standard of care in newly diagnosed transplant-ineligible myeloma patients.

Researchers uncovered distinct clinical characteristics in relapsed/refractory multiple myeloma patients receiving proteasome inhibitors.

Researchers analyzed double vs single autologous stem cell transplantation in patients with newly diagnosed multiple myeloma, after previous conflicting results.

This study looked at the benefit of early therapeutic intervention with the combination of elotuzumab, lenalidomide, and dexamethasone in patients with high-risk smoldering multiple myeloma.

Does patient race play a role in the efficacy of monoclonal antibodies in multiple myeloma?

The ELOQUENT-3 trial looks at how the of addition of elotuzumab to pomalidomide and dexamethasone impacts patient outcomes in multiple myeloma. 

How much do you know about diagnostic imaging's role in multiple myeloma? Take our latest quiz to find out more

FDA approves once-weekly carfilzomib/dexamethasone combo for relapsed or refractory multiple myeloma.

A study shows thalidomide-based treatment carries risk, but could be an option for certain multiple myeloma patients.

Minimal residual disease negativity measured by next-generation sequencing was a valuable prognostic biomarker for multiple myeloma.

Do you know about the quality of life obstacles for multiple myeloma patients? Take our latest quiz to test your knowledge.

The PVX-410 vaccine shows immune responses in a patient population with smoldering myeloma.

A study shows prescription drug coverage leads to better survival among Medicare beneficiaries with multiple myeloma.

How much do you know about the genomics of multiple myeloma? Take our latest quiz to sharpen your knowledge.

A study shows comprehensive sequencing approach can identify treatment options in patients with relapsed and/or refractory myeloma.

Relapsed or refractory multiple myeloma patients experience high response rates, overall survival with bortezomib-based therapy.

A high level of resilience was associated with a better mental and physical health-related quality of life among patients with multiple myeloma.

Are you up-to-date on treatment regimens for previously treated multiple myeloma? Take our latest quiz to sharpen your knowledge.

From 1990 to 2016, incident cases of multiple myeloma increased by 126% globally, while deaths increased 94%. The US had the most incident cases and deaths.

Investigators concluded ixazomib “may offer a more convenient, active, and well-tolerated alternative to a parenterally administered PI in this setting.”

Our latest quiz highlights the role of bone marrow adiposity in patients with multiple myeloma.

An analysis by FDA and NCI investigators recommended further study of the utility of immunotherapy in patients unable to mount adequate immune responses.

Many MM patients experience a diagnostic interval longer than 3 months until diagnosis is confirmed, and several factors may account for this.

Preoperative pain, prothrombin time activity (PTA), albumin, urine protein, and postoperative chemotherapy appeared to be associated with prognosis.